HARROW, INC. HROW
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
1.29
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $272.3M | -$5.1M | $204.4M | $43.0M | $52.4M |
| 2024 | $199.6M | -$17.5M | $150.4M | -$23.8M | $69.3M |
| 2023 | $130.2M | -$24.4M | $90.6M | $2.4M | $70.4M |
| 2022 | $88.6M | -$14.1M | $63.2M | -$892,000 | $27.2M |
| 2021 | $72.5M | -$18.0M | $54.3M | $3.3M | $10.9M |
| 2020 | $48.9M | -$3.4M | $34.4M | -$2.0M | $26.8M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.29 (grey)
- Working capital / assets 0.289
- Retained earnings / assets -0.392
- EBIT / assets 0.076
- Equity / liabilities 0.151
Source: SEC EDGAR filings · CIK 0001360214 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.